Catherine Thieblemont

Professor of Haematology in the Paris University, chair of the Lymphoma group at Hospital Saint-Louis, and head of the hemato-oncology department-Paris, France

Prof Thieblemont ‘s major interest is the biological and clinical features of lymphomas. She is involved in clinical trials for the treatment of lymphoma patients, particularly integrating innovative treatments, such cell immunotherapies and CAR T-cells.

Prof Thieblemont is an active member of the Lymphoma Study Association (LYSA). Within the LYSA, she is one of the members of the steering committee and she is coordinating the committee of the marginal zone lymphoma. She is an active member of the International extranodal Lymphoma study group (IELSG).